WO2022180612A1 - Orodispersible formulation of hypolipidemic agent - Google Patents
Orodispersible formulation of hypolipidemic agent Download PDFInfo
- Publication number
- WO2022180612A1 WO2022180612A1 PCT/IB2022/051711 IB2022051711W WO2022180612A1 WO 2022180612 A1 WO2022180612 A1 WO 2022180612A1 IB 2022051711 W IB2022051711 W IB 2022051711W WO 2022180612 A1 WO2022180612 A1 WO 2022180612A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- weight
- orodispersible
- pharmaceutically acceptable
- tablet
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- 238000009472 formulation Methods 0.000 title claims abstract description 64
- 239000003524 antilipemic agent Substances 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 62
- 150000003839 salts Chemical class 0.000 claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 239000003826 tablet Substances 0.000 claims description 47
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 44
- 229950006544 saroglitazar Drugs 0.000 claims description 27
- -1 glidants Substances 0.000 claims description 20
- UJYFZCVPOSZDMK-YPPDDXJESA-L magnesium (2S)-2-ethoxy-3-[4-[2-[2-methyl-5-(4-methylsulfanylphenyl)pyrrol-1-yl]ethoxy]phenyl]propanoate Chemical compound [Mg++].CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C([O-])=O.CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C([O-])=O UJYFZCVPOSZDMK-YPPDDXJESA-L 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 13
- 229930195725 Mannitol Natural products 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000003085 diluting agent Substances 0.000 claims description 13
- 239000000945 filler Substances 0.000 claims description 13
- 235000010355 mannitol Nutrition 0.000 claims description 13
- 239000000594 mannitol Substances 0.000 claims description 13
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 11
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 11
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 11
- 108010011485 Aspartame Proteins 0.000 claims description 10
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 10
- 239000000605 aspartame Substances 0.000 claims description 10
- 235000010357 aspartame Nutrition 0.000 claims description 10
- 229960003438 aspartame Drugs 0.000 claims description 10
- 239000000796 flavoring agent Substances 0.000 claims description 10
- 235000013355 food flavoring agent Nutrition 0.000 claims description 10
- 229960001855 mannitol Drugs 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 9
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 244000246386 Mentha pulegium Species 0.000 claims description 8
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 8
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 229960000913 crospovidone Drugs 0.000 claims description 8
- 235000001050 hortel pimenta Nutrition 0.000 claims description 8
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 8
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 8
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 8
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 7
- 235000003599 food sweetener Nutrition 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 7
- 210000003296 saliva Anatomy 0.000 claims description 7
- MRWFZSLZNUJVQW-DEOSSOPVSA-N saroglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCN1C(C=2C=CC(SC)=CC=2)=CC=C1C MRWFZSLZNUJVQW-DEOSSOPVSA-N 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 229940032147 starch Drugs 0.000 claims description 7
- 239000003765 sweetening agent Substances 0.000 claims description 7
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims description 6
- 244000144725 Amygdalus communis Species 0.000 claims description 6
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 6
- 229920000881 Modified starch Polymers 0.000 claims description 6
- 235000012550 Pimpinella anisum Nutrition 0.000 claims description 6
- 240000004760 Pimpinella anisum Species 0.000 claims description 6
- 240000007651 Rubus glaucus Species 0.000 claims description 6
- 235000011034 Rubus glaucus Nutrition 0.000 claims description 6
- 235000009122 Rubus idaeus Nutrition 0.000 claims description 6
- 235000017803 cinnamon Nutrition 0.000 claims description 6
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 6
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003086 colorant Substances 0.000 claims description 5
- 239000000395 magnesium oxide Substances 0.000 claims description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 4
- 239000007967 peppermint flavor Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 4
- 239000008109 sodium starch glycolate Substances 0.000 claims description 4
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 4
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims description 3
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 claims description 3
- 241000208140 Acer Species 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 3
- 244000144730 Amygdalus persica Species 0.000 claims description 3
- 244000099147 Ananas comosus Species 0.000 claims description 3
- 235000007119 Ananas comosus Nutrition 0.000 claims description 3
- 240000007087 Apium graveolens Species 0.000 claims description 3
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims description 3
- 235000010591 Appio Nutrition 0.000 claims description 3
- 241000167854 Bourreria succulenta Species 0.000 claims description 3
- 235000004936 Bromus mango Nutrition 0.000 claims description 3
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims description 3
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 3
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims description 3
- 235000005979 Citrus limon Nutrition 0.000 claims description 3
- 235000019499 Citrus oil Nutrition 0.000 claims description 3
- 244000131522 Citrus pyriformis Species 0.000 claims description 3
- 240000000560 Citrus x paradisi Species 0.000 claims description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 3
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 claims description 3
- 244000004281 Eucalyptus maculata Species 0.000 claims description 3
- 239000005770 Eugenol Substances 0.000 claims description 3
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 3
- 240000009088 Fragaria x ananassa Species 0.000 claims description 3
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 3
- 240000001238 Gaultheria procumbens Species 0.000 claims description 3
- 235000007297 Gaultheria procumbens Nutrition 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 241000220225 Malus Species 0.000 claims description 3
- 235000011430 Malus pumila Nutrition 0.000 claims description 3
- 235000015103 Malus silvestris Nutrition 0.000 claims description 3
- 235000014826 Mangifera indica Nutrition 0.000 claims description 3
- 240000007228 Mangifera indica Species 0.000 claims description 3
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 3
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 3
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 3
- 235000005135 Micromeria juliana Nutrition 0.000 claims description 3
- 240000005561 Musa balbisiana Species 0.000 claims description 3
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims description 3
- 235000009421 Myristica fragrans Nutrition 0.000 claims description 3
- 244000270834 Myristica fragrans Species 0.000 claims description 3
- 235000007265 Myrrhis odorata Nutrition 0.000 claims description 3
- 239000004384 Neotame Substances 0.000 claims description 3
- 235000010676 Ocimum basilicum Nutrition 0.000 claims description 3
- 240000007926 Ocimum gratissimum Species 0.000 claims description 3
- 240000000783 Origanum majorana Species 0.000 claims description 3
- 235000006297 Origanum majorana Nutrition 0.000 claims description 3
- 235000009827 Prunus armeniaca Nutrition 0.000 claims description 3
- 244000018633 Prunus armeniaca Species 0.000 claims description 3
- 235000003893 Prunus dulcis var amara Nutrition 0.000 claims description 3
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 3
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims description 3
- 235000014443 Pyrus communis Nutrition 0.000 claims description 3
- 240000001987 Pyrus communis Species 0.000 claims description 3
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 3
- 235000017848 Rubus fruticosus Nutrition 0.000 claims description 3
- 235000007315 Satureja hortensis Nutrition 0.000 claims description 3
- 240000002114 Satureja hortensis Species 0.000 claims description 3
- 235000009184 Spondias indica Nutrition 0.000 claims description 3
- 239000004376 Sucralose Substances 0.000 claims description 3
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 3
- 244000223014 Syzygium aromaticum Species 0.000 claims description 3
- 240000006909 Tilia x europaea Species 0.000 claims description 3
- 235000011941 Tilia x europaea Nutrition 0.000 claims description 3
- 235000009499 Vanilla fragrans Nutrition 0.000 claims description 3
- 244000263375 Vanilla tahitensis Species 0.000 claims description 3
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 3
- 240000006365 Vitis vinifera Species 0.000 claims description 3
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 3
- 235000019498 Walnut oil Nutrition 0.000 claims description 3
- 235000020224 almond Nutrition 0.000 claims description 3
- 229940011037 anethole Drugs 0.000 claims description 3
- 235000021028 berry Nutrition 0.000 claims description 3
- 235000021029 blackberry Nutrition 0.000 claims description 3
- 229940119201 cedar leaf oil Drugs 0.000 claims description 3
- 235000019693 cherries Nutrition 0.000 claims description 3
- 229960005233 cineole Drugs 0.000 claims description 3
- 239000010500 citrus oil Substances 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 239000000686 essence Substances 0.000 claims description 3
- 229960002217 eugenol Drugs 0.000 claims description 3
- 229960001375 lactose Drugs 0.000 claims description 3
- 229960004873 levomenthol Drugs 0.000 claims description 3
- 239000004571 lime Substances 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 3
- 239000001780 majorana hortensis moench (origanum majorana l.) Substances 0.000 claims description 3
- 229940041616 menthol Drugs 0.000 claims description 3
- 229960001047 methyl salicylate Drugs 0.000 claims description 3
- 235000019412 neotame Nutrition 0.000 claims description 3
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims description 3
- 108010070257 neotame Proteins 0.000 claims description 3
- 239000001702 nutmeg Substances 0.000 claims description 3
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 claims description 3
- 235000020043 port wine Nutrition 0.000 claims description 3
- 235000002020 sage Nutrition 0.000 claims description 3
- 239000010670 sage oil Substances 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 235000019408 sucralose Nutrition 0.000 claims description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 3
- 239000001789 thuja occidentalis l. leaf oil Substances 0.000 claims description 3
- 239000010678 thyme oil Substances 0.000 claims description 3
- 239000008170 walnut oil Substances 0.000 claims description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000000378 calcium silicate Substances 0.000 claims description 2
- 229910052918 calcium silicate Inorganic materials 0.000 claims description 2
- 235000012241 calcium silicate Nutrition 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000391 magnesium silicate Substances 0.000 claims description 2
- 235000019792 magnesium silicate Nutrition 0.000 claims description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 2
- 229960003194 meglumine Drugs 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 244000078534 Vaccinium myrtillus Species 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 239000008371 vanilla flavor Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 7
- 239000008187 granular material Substances 0.000 description 22
- 239000002552 dosage form Substances 0.000 description 18
- 239000007916 tablet composition Substances 0.000 description 18
- 239000003814 drug Substances 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 239000000463 material Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 12
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 11
- 239000012535 impurity Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 9
- 239000011230 binding agent Substances 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000005469 granulation Methods 0.000 description 6
- 230000003179 granulation Effects 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 229960002900 methylcellulose Drugs 0.000 description 5
- 239000006186 oral dosage form Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000518994 Conta Species 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000007908 dry granulation Methods 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000007962 solid dispersion Substances 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 235000020937 fasting conditions Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 229960002737 fructose Drugs 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- 229940035436 maltitol Drugs 0.000 description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical compound O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000004377 Alitame Substances 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 241001092459 Rubus Species 0.000 description 2
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 2
- 229960005164 acesulfame Drugs 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 235000019409 alitame Nutrition 0.000 description 2
- 108010009985 alitame Proteins 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 2
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 2
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 235000013980 iron oxide Nutrition 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960001462 sodium cyclamate Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 239000000892 thaumatin Substances 0.000 description 2
- 235000010436 thaumatin Nutrition 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000015337 arteriosclerotic cardiovascular disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960000892 attapulgite Drugs 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- HRBZRZSCMANEHQ-UHFFFAOYSA-L calcium;hexadecanoate Chemical compound [Ca+2].CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC([O-])=O HRBZRZSCMANEHQ-UHFFFAOYSA-L 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000000871 hypocholesterolemic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 235000021579 juice concentrates Nutrition 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 235000019659 mouth feeling Nutrition 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- AYOOGWWGECJQPI-NSHDSACASA-N n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound N1C(OC(C)C)=CC(N2C3=NC(N[C@@H](C)C=4N=CC(F)=CN=4)=CC=C3N=C2)=N1 AYOOGWWGECJQPI-NSHDSACASA-N 0.000 description 1
- 229960000619 nebivolol Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940079938 nitrocellulose Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229910052625 palygorskite Inorganic materials 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229940117958 vinyl acetate Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- KMIOJWCYOHBUJS-HAKPAVFJSA-N vorolanib Chemical compound C1N(C(=O)N(C)C)CC[C@@H]1NC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C KMIOJWCYOHBUJS-HAKPAVFJSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Definitions
- Present invention relates to orodispersible formulation of suitable hypolipidemic agent.
- the present invention discloses novel orodispersible formulation of the compound of formula (I), or its pharmaceutically acceptable salts and preparation of such stable pharmaceutical formulations.
- ODTs Orally Disintegrating Tablets
- ODT dosage forms Several factors must be considered when selecting drug candidates for delivery as ODT dosage forms.
- an ODT is formulated as a bioequivalent line extension of an existing oral dosage form. Under this circumstance, it is assumed that the absorption of a drug molecule from the ODT occurs in the postgastric GIT segments, similar to the conventional oral dosage form. But this scenario may not always be the case.
- An ODT may have varying degrees of pregastric absorption and thus, the pharmacokinetic profiles may vary (9). Therefore, the ODT may not be bioequivalent to the conventional oral dosage form.
- ODT formulations which have significantly different pharmacokinetic profiles compared with the same dose administered in a conventional dosage form.
- the compound of Formula (I) are useful to prevent or reduce the risk of developing atherosclerosis, which leads to disease and condition selected from arteriosclerotic cardiovascular diseases, stroke, coronary heart diseases, cerebrovascular disease, peripheral vessel diseases and related disorders.
- WO 03009841 discloses compounds of the following general formula:
- Formula (I) Saroglitazar magnesium of compound of Formula (I-a) and its use in lipodystrophy is described in WO 201210486; the contents of which are incorporated herein by reference.
- the compound of Formula (I-a) are useful in the treatment of diabetes mellitus type 2, and/or non-alcoholic steatohepatitis and/or Non-alcoholic fatty lever diseases (NAFLD) and/or Primary biliary cholangitis (PBC).
- WO 2018104916 disclosed a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for use in treating primary biliary cholangitis.
- WO 2015011730 disclosed a stable pharmaceutical composition of Saroglitazar of compound of formula (I) or its pharmaceutically acceptable salts comprising compounds of formula (I) or its pharmaceutically acceptable salts, wherein the pH of the formulation is maintained above 7.
- the orodispersible tablets of the present invention show rapid disintegration in the buccal cavity upon contact with saliva without chewing, have a pleasant taste and palatability and thus better patient convenience and acceptance due to ease of administration and ingestion.
- the present invention describes a orodispersible formulation of compounds of formula (I) or its pharmaceutically acceptable salts.
- the present invention describes a stable orodispersible formulation of Saroglitazar magnesium of compound of formula (I-a).
- the present invention further describes a stable orodispersible formulation of compounds of formula (I) or it’s pharmaceutically acceptable salts comprise one or more pharmaceutical excipients.
- an orodispersible formulation comprising Saroglitazar compound of formula (I) or its pharmaceutically acceptable salts.
- an orodispersible formulation comprising compound of formula (I) Saroglitazar or its pharmaceutically acceptable salts and pharmaceutically acceptable excipient.
- an orodispersible formulation comprising compound of formula (I)
- a diluent or filler wherein the diluent or filler is mannitol where 10 % of particles should not be more than 315 ⁇ m and 90 % of particles should not be less than 75 ⁇ m;
- a stable orodispersible tablet formulation which disintegrates rapidly by the action of saliva in the oral cavity.
- the orodispersible tablet of the present invention disintegrates in less than 60 seconds, preferably in less than 40 seconds.
- the invention further provides a stable orodispersible tablet formulation of compound of formula (I) or its pharmaceutically acceptable salts preferably compound of formula (I-a) suitable for treatment of primary biliary cholangitis (PBC).
- the term “rapidly disintegrating tablet in the buccal cavity ” in the present invention shall mean a tablet that can rapidly and completely disintegrate in the oral cavity only by saliva without water.
- the term “orodispersible tablet” or “ODT” refer to a solid dosage form of the present invention, which disintegrates rapidly in the oral cavity of a patient after administration, without chewing. The rate of disintegration can vary, but faster than the rate of disintegration of conventional solid dosage forms or chewable solid dosage forms which are intended to be swallowed immediately after administration.
- method of treatment means any treatment of a disease or disorder in a mammal, including: preventing or protecting against the disease or disorder, that is, causing the clinical symptoms not to develop; inhibiting the disease or disorder, that is, arresting or suppressing the development of clinical symptoms; and/or relieving the disease or disorder, that is, causing the regression of clinical symptoms.
- C max refers to maximum plasma concentration
- (AUC 0-t ) used herein refers to area under theconcentration-time curve fromtime zero to time t.
- T max refers to time to maximum concentration
- pharmaceutically acceptable indicates that the material does not have properties that would cause one of skill in the art to avoid administration of the material to a patient, taking into consideration the disease or conditions to be treated and the respective route of administration. Further, the material is considered to be safe for administration in humans or animals.
- Patient includes both human and animals.
- “Mammal” means humans and other mammalian animals.
- excipient(s) or " pharmaceutically acceptable excipient(s)” refers to pharmacologically inactive substances that are added to a pharmaceutical preparation in addition to the active pharmaceutical ingredient. Excipients may take the function of vehicles, diluents/fillers, disintegration or dissolution modifying agents, absorption enhancers, stabilizers or a manufacturing aid among others. Excipients may include fillers, diluents/fillers, binders, disintegrating agents, lubricants, stabilizers and glidants. Examples of excipients classes frequently used are listed below.
- binder is intended to mean substances used to cause adhesion of powder particles in tablet granulations.
- Such compounds include, by way of example and without limitation, acacia, alginic acid, tragacanth, carboxymethylcellulose sodium, compressible sugar (e.g., NuTab), ethylcellulose, gelatin, liquid glucose, methylcellulose, povidone and pregelatinized starch, combinations thereof and other similar material known to those of ordinary skill in the art.
- binders include starch, poly(ethylene glycol), guar gum, polysaccharide, bentonites, sugars, invert sugars, poloxamers (PLURONIC F68, PLURONIC F127), collagen, albumin, celluloses in nonaqueous solvents, and the like or their suitable combinations.
- Other binders which may be included may be, for example, poly(propylene glycol), polyoxyethylene - polypropylene copolymer, polyethylene ester, polyethylene sorbitan ester, poly(ethylene oxide), microcrystalline cellulose, poly(vinylpyrrolidone), combinations thereof and other such materials known to those of ordinary skill in the art.
- the term "diluent” or “filler” is intended to mean inert substances used as fillers to create the desired bulk, flow properties, and compression characteristics in the preparation of tablets and capsules.
- Such compounds include, by way of example and without limitation, dibasic calcium phosphate, kaolin, sucrose, lactose, mannitol, maltodextrin, fructose, maltitol, xylitol, sucrose, microcrystalline cellulose, silicified microcrystalline cellulose, powdered cellulose, precipitated calcium carbonate, sorbitol, starch, pregelantized starch, hydrated sodium sulfoaluminate combinations thereof and other such materials known to those of ordinary skill in the art.
- glidant is intended to mean agents used in tablet and capsule formulations to improve flow-properties during tablet compression and to produce an anti caking effect.
- Such compounds include, by way of example and without limitation, colloidal silica, calcium silicate, magnesium silicate, silicon hydrogel, corn starch, talc, ascorbil palmitate, calcium palmitate, combinations thereof and other such materials known to those of ordinary skill in the art.
- lubricant is intended to mean substances used in tablet formulations to reduce friction during tablet compression.
- Such compounds include, by way of example and without limitation, calcium stearate, magnesium stearate, sodium stearate, sodium steryl fumarate, talc, sodium lauryl sulfate, mineral oil, stearic acid, zinc stearate, suitable combinations thereof and other such materials known to those of ordinary skill in the art.
- disintegrant is intended to mean a compound used in solid dosage forms to promote the disruption of the solid mass into smaller particles which are more readily dispersed or dissolved.
- exemplary disintegrants include, by way of example and without limitation, starches such as com starch, potato starch, pre-gelatinized and modified starch (Starch 1500) thereof, sweeteners, clays, such as bentonite, croscarmellose sodium, microcrystalline cellulose (e.g.
- AvicelTM. crospovidone
- polacrilin potassium methyl cellulose sodium CMC, calcium CMC
- HPMC alginates
- alginic acid low substituted HPC
- sodium starch glycolate gums such as agar, guar, locust bean, karaya, pectin, tragacanth, combinations thereof and other such materials known to those of ordinary skill in the art.
- stabilizers are the compound that maintain the pH of the formulation used according to the present invention include, but are not limited to attapulgite, bentonite, calcium carbonate, calcium phosphate, calcium sulphate, mono ethanolamine, tri ethanolamine, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium benzoate, sodium hydroxide, sodium citrate, sodium sulfite, sodium bicarbonate, sodium carbonate, disodium hydrogen phosphate, mono basic potassium phosphate, dicalcium phosphate, meglumine, light or heavy magnesium oxide and other similar excipients and their suitable combinations and other materials known to those of ordinary skill in the art.
- carrier polymer is intended to mean substances used to act as carrier to form complex with API and enhance solubility.
- Such compounds include, by way of example and without limitation, alkylcellulose such as methylcellulose; hydroxyalkylcellulose such as hydroxyethylcellulose and hydroxypropylcellulose; hydroxyalkylalkylcellulose such as hydroxyethylmethylcellulose and hydroxypropylmethylcellulose; hypromellose acetate succinate, methylcellulose phthalate, cellulose acetate phthalate, polyethylene glycol, ethylcellulose, pyroxylin, polyethylene oxide, polyvinyl caprolactam-polyvinyl acetate -polyethylene glycol, hydroxypropyl methylcellulose phthalate, hydroxybutylcellulose, carboxymethylcellulose, 60:40 copolymer of N-vinyl-2-pyrrolidone and vinylacetate, sodium carboxymethylcellulose, carboxymethyl- ethylcellulose, cellulose acetate phthalate
- the sweetener in the formulations of the present invention selected from a group comprising isomalt, sorbitol, acesulfame, aspartame, alitame, fructose, maltitol, lactitol, xylitol, erythritol, saccharin, sodium cyclamate, sucralose, sucrose, neotame, neohespiridine dihydrochalcone, glycyrrhizin, stevloside, thaumatin, tagatose or suitable combination thereof.
- the flavouring agent in the formulations of the present invention selected from a group comprising levomenthol, menthol, anethole, methyl salicylate, eucalyptol, cinnamon, mint, mango, almond, anise, celery, cassia, nutmeg rosemary, savory, basil, sweet marjoram, wintergreen, peppermint, 1-methyl acetate, sage, eugenol, oxanone, lemon, orange, strawberry, blackberry, raspberry, banana, butterscotch, coconut-custard, cinnamon , grinatidine, portwine, gaulterial, peppermint, clove, berry, aniseed, eucalyptus, thyme oil, cedar leaf oil, walnut oil, sage oil, bitter almonds, vanilla, citrus oil, including grape, lime and grapefruit, and fruit essences, including apple, pear, peach, raspberry, cherry, maple, plum, pineapple, apricot or combinations thereof.
- solvents is intended to mean a compound or mixture of more than one used to dissolve the API and the carrier polymer in one phase.
- the solvent may include, without limitation, water, methanol, ethanol, methylene chloride, acetone, methyl acetate, ethyl acetate, chlorinated solvents, N-methylpyrrolidone (NMP), dimethylsulfoxide (DMSO) or dimethylacetamide (DMAc), n-propanol, isopropanol, butanol, methyl ethyl ketone and methyl isobutyl ketone, ethyl acetate and propylacetate, acetonitrile, toluene, 1,1,1-trichloroethane or suitable combinations thereof.
- NMP N-methylpyrrolidone
- DMSO dimethylsulfoxide
- DMAc dimethylacetamide
- Suitable coloring agents include, one or more natural and/or artificial colorants such as FD&C coloring agents, natural juice concentrates, pigments such as titanium oxide, silicon dioxide, iron oxides, zinc oxide, and the like.
- FD&C coloring agents natural juice concentrates
- pigments such as titanium oxide, silicon dioxide, iron oxides, zinc oxide, and the like.
- the present invention provides a stable orodispersible formulation of compounds of formula (I)
- the present invention provides a stable orodispersible tablet formulation of saroglitazar magnesium of compound of formula (I-a).
- Formula (I-a) The present invention further describes a stable orodispersible formulation of compounds of formula (I) or its pharmaceutically acceptable salts preferably a compound of formula (I-a), comprising one or more pharmaceutical excipients.
- the orodispersible formulation of compound of formula (I) or its pharmaceutically acceptable salts, preferably a compound of formula (I-a) of the present invention essentially comprises of
- a diluent or filler wherein the diluent or filler is mannitol where 10 % of particles should not be more than 315 ⁇ m and 90 % of particles should not be less than 75 ⁇ m;
- a disintegrating agent (ii) a disintegrating agent; (iii) a soluble excipients component part more than 50%w/w. (iv) and one or more pharmaceutically acceptable excipient.
- Suitable disintegrating agent in the formulations of the present invention selected from a group comprising croscarmellose sodium, crospovidone, pregelatinized starch, sodium starch glycolate or low-substituted hydroxypropyl cellulose.
- Soluble excipients component part is selected from mannitol, lactose, aspartame or mixture thereof.
- the other pharmaceutical excipients according to the present invention can be selected from stabilizers, binders, lubricants, glidants, sweeteners, carrier polymer, solvents, flavoring agents and colors and the like as known in the art.
- the sweetener in the formulations of the present invention selected from a group comprising isomalt, sorbitol, acesulfame, aspartame, alitame, fructose, maltitol, lactitol, xylitol, erythritol, saccharin, sodium cyclamate, sucralose, sucrose, neotame, neohespiridine dihydrochalcone, glycyrrhizin, stevloside, thaumatin, tagatose or suitable combination thereof.
- the flavouring agent in the formulations of the present invention selected from a group comprising levomenthol, menthol, anethole, methyl salicylate, eucalyptol, cinnamon, mint, mango, almond, anise, celery, cassia, nutmeg rosemary, savory, basil, sweet marjoram, wintergreen, peppermint, 1-methyl acetate, sage, eugenol, oxanone, lemon, orange, strawberry, blackberry, raspberry, banana, butterscotch, coconut-custard, cinnamon , grinatidine, portwine, gaulterial, peppermint, clove, berry, aniseed, eucalyptus, thyme oil, cedar leaf oil, walnut oil, sage oil, bitter almonds, vanilla, citrus oil, including grape, lime and grapefruit, and fruit essences, including apple, pear, peach, raspberry, cherry, maple, plum, pineapple, apricot or combinations thereof.
- Suitable gelling matrix forming agents include, without limitation, gelling gelatin, carageenan gums, hyaluronic acid, pectins, sodium pectate, starches, carboxymethyl cellulose sodium, agar, gellan gum, xanthan gum, guar gum, tragacanthan gum, hydroxypropyl cellulose, hydroxyethyl cellulose hydroxypropyl methylcellulose, methylcellulose, carbopols, carbomers, poloxamer, polyacrylic acid, polyvinyl alcohol, alginates and poly(glycolic acid) or suitable combinations thereof. Any of excipients may have more than one role in formulation for example starch used as both binder and glidant in formulation.
- orodispersible formulation according to the present invention comprises from about 0.5 % to about 10 % w/w compound of Formula (I-a).
- the present invention provides a stable orodispersible tablet formulation which disintegrates rapidly by the action of saliva in the oral cavity.
- the orodispersible tablet of the present invention disintegrates in less than 60 seconds, preferably in less than 40 seconds.
- the orodispersible tablet formulation of the present invention comprises compound of formula (I) or its pharmaceutically acceptable salts, preferably compound of formula (I-a) having particle size (D90) of is less than 200 ⁇ m, preferably less than 100 ⁇ m, more preferably less than 75 ⁇ m.
- the orodidpersable formulation of the present invention comprise orodispersable tablet formulation of compound of formula (I) or its pharmaceutically acceptable salts, preferably compound of formula (I-a) with good disintegration characteristics and pharmacokinetics, which provide improved compliance for patients in need thereof.
- the orodispersible tablet formulation of the present invention may further comprise one or more known impurities and if present their individual limit should not be more than 1.5 %.
- the orodispersible tablet formulation of the present invention may further comprise one or more unknown impurities and if present their individual limit should not be more than 0.5%.
- the orodispersible tablet formulation comprising a therapeutically effective amount of compound of formula (I) or its pharmaceutically acceptable salt preferably compound of formula (I-a) and a pharmaceutically acceptable excipient, wherein the composition provides a serum or plasma profile comprising a mean of C max of from about 19.50 ng/ml to about 850 ng/ml, when administered to the patient in need thereof.
- the pharmaceutical composition comprising a therapeutically effective amount of compound of formula (I) or its pharmaceutically acceptable salt preferably compound of formula (I-a) and a pharmaceutically acceptable excipient, wherein the composition provides a serum or plasma profile comprising a mean of AUC last of from about 46.50 hr*ng/ml to about 2050 hr*ng/ml, when administered to the patient in need thereof.
- the pharmaceutical composition comprising a therapeutically effective amount of compound of formula (I) or its pharmaceutically acceptable salt preferably compound of formula (I-a) and a pharmaceutically acceptable excipient, wherein the composition provides a serum or plasma profile comprising a T max of from about 0.25 hr to about 2.0 hr, when administered to the patient in need thereof.
- the orodispersible tablet formulation of the present invention may be packed in suitable size HDPE bottle pack or Blister pack or Blister in pouch pack using appropriate desiccant and/or oxygen scavenger and/or packaging component under nitrogen environment. This may help to stabilize the drug product to control the moisture and oxygen sensitive impurities.
- Orodispersible formulation according to the present invention may be in the form of a tablet or capsule or a powder or a suspension in a liquid or an aerosol formulation or solutions, preferably in the form of a tablet.
- the orodispersible formulations prepared according to the present invention comprise Saroglitazar magnesium in the range of about 0.5% to about 8 % (w/w), disintegrant in the range of about 1% to about 10 % (w/w), binder in the range of about 0.1 % to about 15 %, diluent in the range of about 5 % to about 90% (w/w), wetting agent in the range of about 2 % to about 20%, alkanilizer agent in the range of about 1% to about 16% (w/w), glidant in the range of about 0.1% to about 2.0 % (w/w), sweetener in the range of about 0.1% to about 50% (w/w), antioxidant in the range of about 0.1 % to about 10 %, gelling matrix forming agent in the range of about 0.1% to about 20%, carrier polymer in the range of about 0.5% to about 50%, solvents in the range of about 2% to about 90%, flavoring agent in the range of about 0.1% to about 8 % (w/w),
- the orodispersible formulation may be made by direct compression, wet granulation, dry granulation, lyophilization, solid dispersion or top spray granulation methods by techniques known to persons skilled in the art.
- direct compression wet granulation, dry granulation, lyophilization, solid dispersion or top spray granulation methods by techniques known to persons skilled in the art.
- the drug is mixed with one or more pharmaceutical excipients and granulated with suitable binding solution as described earlier, to form wet granules; the wet granules are dried and optionally sieved. The dried granules are mixed with one or more suitable excipients from those described elsewhere and then compressed into tablets or filled into capsules.
- the drug In direct compression process, the drug is mixed with all the pharmaceutical excipients required and then is compressed into tablets.
- the drug is mixed with one or more pharmaceutical excipients and compressed into slugs and these slugs are passed through required size of sieve.
- the sieved granules are mixed with one or more suitable excipients from those described elsewhere and then compressed into tablets or filled into capsules.
- lyophilization process the drug is suspended in water with one or more suitable pharmaceutical excipients with or without help of homogenization.
- the resultant suspension is accurate filled in suitable aluminum blister and lyophilized.
- the lyophilized tablets are sealed in the blister pack.
- the drug and a suitable polymer are dissolved in a common solvent or mixture of solvents to form drug polymer complex.
- the remaining excipients are passed through required size of sieve and granulated with the drug polymer solution under controlled process.
- the wet granules are dried and optionally sieved.
- the dried granules are mixed with one or more suitable excipients from those described elsewhere and then compressed into tablets.
- top spray granulation process the drug is dissolved in a suitable solvent or mixture of solvents.
- the bulk of one or more excipients are passed through appropriate size of sieve and granulated with the drug solution under controlled process.
- the wet granules are dried and optionally sieved.
- the dried granules are mixed with one or more suitable excipients from those described elsewhere and then compressed into tablets.
- Manufacturing process comprises following techniques: 1. Wet Granulation
- the invention is further exemplified by the following non-limiting example, which is illustrative representing the preferred modes of carrying out the invention.
- the invention’s scope is not limited to these specific embodiments only but should be read in conjunction with what is disclosed anywhere else in the specification together with those information and knowledge that are within the general understanding of a person skilled in the art.
- Magnesium oxide light is mixed with remaining quantity of mannitol and sifted through sieve #30.
- step 3 Half material of step 3 and complete material of step 2 and then remaining half material of step 3 are added in conta blender and blended for 5 min at 18 RPM. 5. Iron oxide red is sifted with of microcrystalline cellulose through sieve #40 and kept aside.
- Magnesium stearate is sifted through #60 and added into step 6 and blend is lubricated for 5 min at 18 RPM.
- magnesium oxide and compound of formula (I-a) are suspended in to it under stirring.
- step 2 The suspension of step 2 is homogenized using high speed homogenizer.
- the resultant suspension is accurately filled by specified weight in to pockets of aluminum blister and lyophilized.
- the prepared tablets are packed in the blisters pack.
- Intragranular excipients magnesium oxide light, mannitol, crospovidone and microcrystalline cellulose are weighed accurately and mixed properly in suitable granulator.
- step 3 API polymer solution is added and the blend is granulated.
- step 4 The wet mass of step 3 is passed through # 10 and the wet granules are dried in fluid bed dryer at temperature below 35°C.
- step 4 The dried granules of step 4 are milled to get uniform granules.
- Colloidal silicon dioxide, peppermint flavor and aspartame are weighed and passed along with the milled granules of step 5 through # 30.
- the final blend is compressed to make the tablet dosage form.
- Intragranular excipients magnesium oxide light, mannitol, crospovidone and microcrystalline cellulose are weighed accurately and mixed and loaded in to fluidized bed granulator.
- the dry blend is granulated using the API solution using top spray granulation technique.
- step 3 The wet granules of step 3 are dried in fluid bed dryer at temperature below 35°C.
- step 4 The dried granules of step 4 are milled to get uniform granules.
- Colloidal silicon dioxide, peppermint flavor and aspartame are weighed and passed along with the milled granules of step 5 through # 30.
- the final blend is compressed to make the tablet dosage form.
- Suitable intragranular excipients and compound of formula (I- a) are weighed accurately and mixed properly in suitable granulator.
- IPA is added and the blend is granulated.
- the wet mass is passed through # 10 and the wet granules are dried in fluid bed dryer at temperature below 60°C.
- the dried granules are milled to get uniform granules.
- Colloidal silicon dioxide, peppermint flavor and aspartame are weighed and passed along with the dried granules through # 30.
- the above blend is mixed with the granules in the conta blender and to the dried mass; talc and magnesium stearate are added and mixed.
- the final blend is compressed to make the tablet dosage form. 2.0 Dry granulation
- Suitable excipients and compound of formula (I-a) are mixed and passed through a roller compactor. Obtained compressed powder/slug is then subjected to milling to get uniform particle size granules which are further lubricated and compressed to make tablet dosage form.
- Table 1 given below shows stability data of stable orodispersible tablet formulation of Example- 1 as exemplified above.
- Tables 2, 3 and 4 given below show analytical data of orodispersible tablet formulation of Example-6, Example-7 and Example-8 respectively as exemplified above.
- Table 5 given below shows stability data of stable orodispersible tablet formulation of Example-4 as exemplified above.
- Saroglitazar magnesium ODT dosage form have better advantage over conventional immediate release (IR) dosage form, where disintegration time is observed less than 60 seconds.
- Saroglitazar magnesium ODT having higher soluble fraction of excipients (more than 70%) as well as sweetner and flavoring agents which make ODT formulation more patient compliant. The higher soluble fraction of excipient along with sweetner and flavoring agent renders pleasant mouth feeling.
- IR formulation of Saroglitazar as mentioned here can be prepared according to the US patent No. US 10098868 B2.
- Table 6 given below shows comparative data of stable orodispersible tablet formulation and IR formulation of Compound of formula (I) or its pharmaceutically salts, preferably Compound of formula (I- a).
- Table 7 shows comparative In-vitro dissolution data of stable ODT formulation and IR formulation. Despite of change in the formulation composition of Saroglitazar magnesium ODT formulation, the dissolution profile of Saroglitazar magnesium ODT formulation found comparable to conventional IR formulation.
- Test Product Saroglitazar magnesium OD tablet 2 mg
- Test Product After an overnight fasting of at least 10 hours, subjects were administered a single 2 mg oral dose of Test Product in a sitting posture without drinking water as per randomization schedule. Subjects were required to place the Test Product on the tongue without crushing or breaking the tablet with teeth till it completely dispersed in saliva and then subjects were allowed to swallow the content without administration of water. Subjects were allowed to wet the mouth by swallowing 20 ml of 20% Glucose solution 10 min before placing the ODT on the tongue.
- Reference Product After an overnight fasting of at least 10 hours, subjects were administered a single 2 mg oral dose of Reference Product in a sitting posture with about 240 ⁇ 2 mL of 20% Glucose solution at ambient temperature as per randomization schedule.
- Pfister WR, Ghosh TK Intraoral delivery systems: An overview, current status and future trends. In: Pfister WR, Ghosh TK (Eds). Drug delivery to the oral cavity: Molecules to Market. CRC Press, NY, USA, 2005, 1-40.
Abstract
Present invention relates to orodispersible formulation of suitable hypolipidemic agent. Preferably, the present invention discloses novel orodispersible formulation of the compound of formula (I), or its pharmaceutically acceptable salts and preparation of such stable pharmaceutical formulations.
Description
ORODISPERSIBLE FORMULATION OF HYPOLIPIDEMIC AGENT
FIELD OF THE INVENTION:
Present invention relates to orodispersible formulation of suitable hypolipidemic agent. Preferably, the present invention discloses novel orodispersible formulation of the compound of formula (I), or its pharmaceutically acceptable salts and preparation of such stable pharmaceutical formulations.
BACKGROUND OF THE INVENTION
For the past one decade, there has been an enhanced demand for more patient-friendly and compliant dosage forms. As a result, the demand for developing new technologies has been increasing annually (1). Since the development cost of a new drug molecule is very high, efforts are now being made by pharmaceutical companies to focus on the development of new drug dosage forms for existing drugs with improved safety and efficacy together with reduced dosing frequency, and the production of more cost effective dosage forms. For most therapeutic agents used to produce systemic effects, the oral route still represents the preferred way of administration, owing to its several advantages and high patient compliance compared to many other routes (2). Tablets and hard gelatin capsules constitute a major portion of drug delivery systems that are currently available. However, many patient groups such as the elderly, children, and patients who are mentally retarded, uncooperative, nauseated, or on reduced liquid-intake/diets have difficulties swallowing these dosage forms. Those who are traveling or have little access to water are similarly affected (3-5). To fulfill these medical needs, pharmaceutical technologists have developed a novel oral dosage form known as Orally Disintegrating Tablets (ODTs) which disintegrate rapidly in saliva, usually in a matter of seconds, without the need to take it with water. Drug dissolution and absorption as well as onset of clinical effect and drug bioavailability may be significantly greater than those observed from conventional dosage forms (6-8).
Several factors must be considered when selecting drug candidates for delivery as ODT dosage forms. In general, an ODT is formulated as a bioequivalent line extension of an existing oral dosage form. Under this circumstance, it is assumed that the absorption of a drug molecule from the ODT occurs in the postgastric GIT segments, similar to the conventional oral dosage form. But this scenario may not always be the case. An ODT may have varying degrees of pregastric absorption and thus, the pharmacokinetic profiles may vary (9). Therefore, the ODT may not be bioequivalent to the conventional oral dosage form.
There are various examples of ODT formulations which have significantly different pharmacokinetic profiles compared with the same dose administered in a conventional dosage form. For example ODT formulations of selegiline, apomorphine, buspirone, orodispersible tablet of Carvidilol (Drug Design, Development and Therapy 2015:9 1379- 1392), Orodispersible tablet of Nebivolol (Journal of Pharmaceutical Investigation:
December 2014) have significantly different pharmacokinetic profiles compared with the same dose administered in a conventional dosage form (10,11).
The compound of Formula (I) are useful to prevent or reduce the risk of developing atherosclerosis, which leads to disease and condition selected from arteriosclerotic cardiovascular diseases, stroke, coronary heart diseases, cerebrovascular disease, peripheral vessel diseases and related disorders.
Various compounds as hypolipidaemic and hypocholesterolemic compounds are disclosed in PCT application no. W001053257 and W003009841 as well as processes for their preparation. WO 03009841 discloses compounds of the following general formula:
Formula (I) Saroglitazar magnesium of compound of Formula (I-a) and its use in lipodystrophy is described in WO 201210486; the contents of which are incorporated herein by reference. The compound of
Formula (I-a) are useful in the treatment of diabetes mellitus type 2, and/or non-alcoholic steatohepatitis and/or Non-alcoholic fatty lever diseases (NAFLD) and/or Primary biliary cholangitis (PBC).
Formula (I-a)
WO 2018104916 disclosed a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for use in treating primary biliary cholangitis.
WO 2015011730 disclosed a stable pharmaceutical composition of Saroglitazar of compound of formula (I) or its pharmaceutically acceptable salts comprising compounds of formula (I) or its pharmaceutically acceptable salts, wherein the pH of the formulation is maintained above 7.
In order to obtain marketing approval for a new drug product, manufacturers must submit to the regulatory authority evidence that the product is acceptable for administration to humans. Such a submission must include impurity profile of the product to demonstrate that the impurities are either absent, or present in a negligible amount. Different regulatory authorities have promulgated guidelines requiring applicants to identify the impurities present in the product and also disclose their concentration in the product. They also provide the axi um level of impurities allowable in the product. Thus for e.g. USFDA (United States Food and Drug Administration) recommends that drug applicants identify all the impurities having concentration of 0.1 % or greater in the active ingredient. Therefore, there is a need to check impurity profile and identify the impurities and also their concentration in the active ingredient or in finish drug product.
Some of the impurities of the compound of formula (I) or its pharmaceutically acceptable salts have been disclosed in WIPO patent application no. WO2017064635 and Indian Patent application no. IN 201921010391.
The handling and storage particularly in the bulk form of pharmaceutically active ingredients which are sensitive to oxidation is difficult. Special handling is necessary and often the oxidation-sensitive ingredient is stored in airtight packaging under protective gas. The compounds of formula (I) or its pharmaceutically acceptable salts are susceptible to oxidation, alkaline & acid hydrolysis and stress degradation during synthesis and purification of the drug substance or when formulated as a dosage form.
Accordingly, there is a need to develop alternate formulation which can stabilize the compound of formula (I) or its pharmaceutically acceptable salts with desirable PK and bulk physical properties. The orodispersible tablets of the present invention show rapid disintegration in the buccal cavity upon contact with saliva without chewing, have a pleasant taste and palatability and thus better patient convenience and acceptance due to ease of administration and ingestion.
SUMMARY OF THE INVENTION
The present invention describes a orodispersible formulation of compounds of formula (I) or its pharmaceutically acceptable salts. Preferably, the present invention describes a stable orodispersible formulation of Saroglitazar magnesium of compound of formula (I-a).
The present invention further describes a stable orodispersible formulation of compounds of formula (I) or it’s pharmaceutically acceptable salts comprise one or more pharmaceutical excipients. EMBODIMENTS OF THE PRESENT INVENTION
In an embodiment, there is provided an orodispersible formulation comprising Saroglitazar compound of formula (I) or its pharmaceutically acceptable salts.
In another embodiment, there is provided an orodispersible formulation comprising compound of formula (I) Saroglitazar or its pharmaceutically acceptable salts and pharmaceutically acceptable excipient.
In a preferred embodiment, there is provided an orodispersible formulation comprising compound of formula (I)
Formula (I) or its pharmaceutically acceptable salt comprising,
(i) a diluent or filler, wherein the diluent or filler is mannitol where 10 % of particles should not be more than 315 μm and 90 % of particles should not be less than 75 μm;
(ii) a disintegrating agent;
(iii) a soluble excipients component part more than 50%w/w.
(iv) and one or more pharmaceutically acceptable excipient.
In a further embodiment, there is provided a stable orodispersible tablet formulation which disintegrates rapidly by the action of saliva in the oral cavity. In an embodiment, the orodispersible tablet of the present invention disintegrates in less than 60 seconds, preferably in less than 40 seconds.
In yet another embodiment, there is provided a process for the preparation of stable orodispersible tablet formulation of compound of formula (I) or its pharmaceutically acceptable salts preferably compound of formula (I-a).
In yet another embodiment the invention further provides a stable orodispersible tablet formulation of compound of formula (I) or its pharmaceutically acceptable salts preferably compound of formula (I-a) suitable for treatment of primary biliary cholangitis (PBC). In a further embodiment, there is provided a use of stable orodispersible tablet formulation of compound of formula (I) or its pharmaceutically acceptable salts preferably compound of formula (I-a) for treating diseases or disorders associated with primary biliary cholangitis (PBC).
DETAILED DESCRIPTION OF THE INVENTION: The term “rapidly disintegrating tablet in the buccal cavity ” in the present invention shall mean a tablet that can rapidly and completely disintegrate in the oral cavity only by saliva without water.
The term “orodispersible tablet” or “ODT” refer to a solid dosage form of the present invention, which disintegrates rapidly in the oral cavity of a patient after administration, without chewing. The rate of disintegration can vary, but faster than the rate of disintegration of conventional solid dosage forms or chewable solid dosage forms which are intended to be swallowed immediately after administration.
The term “about” as used herein is intended to mean approximately, in the region of, roughly, or around. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term “about” is used herein to modify a numerical value above and below the stated value by a variance of 10%.
The term “ method of treatment ” as used herein, means any treatment of a disease or disorder in a mammal, including: preventing or protecting against the disease or disorder, that is, causing the clinical symptoms not to develop; inhibiting the disease or disorder, that is, arresting or suppressing the development of clinical symptoms; and/or relieving the disease or disorder, that is, causing the regression of clinical symptoms.
The term “Cmax ” as used herein refers to maximum plasma concentration.
The term “(AUC0-t) " used herein refers to area under theconcentration-time curve fromtime zero to time t.
The term “Tmax ” as used herein refers to time to maximum concentration.
The term "pharmaceutically acceptable" indicates that the material does not have properties that would cause one of skill in the art to avoid administration of the material to a patient, taking into consideration the disease or conditions to be treated and the respective route of administration. Further, the material is considered to be safe for administration in humans or animals.
" Patient " includes both human and animals. "Mammal" means humans and other mammalian animals.
The term "excipient(s)" or " pharmaceutically acceptable excipient(s)" refers to pharmacologically inactive substances that are added to a pharmaceutical preparation in addition to the active pharmaceutical ingredient. Excipients may take the function of vehicles,
diluents/fillers, disintegration or dissolution modifying agents, absorption enhancers, stabilizers or a manufacturing aid among others. Excipients may include fillers, diluents/fillers, binders, disintegrating agents, lubricants, stabilizers and glidants. Examples of excipients classes frequently used are listed below.
As used herein, the term "binders" is intended to mean substances used to cause adhesion of powder particles in tablet granulations. Such compounds include, by way of example and without limitation, acacia, alginic acid, tragacanth, carboxymethylcellulose sodium, compressible sugar (e.g., NuTab), ethylcellulose, gelatin, liquid glucose, methylcellulose, povidone and pregelatinized starch, combinations thereof and other similar material known to those of ordinary skill in the art.
When needed, other binders may also be included in the present invention. Exemplary binders include starch, poly(ethylene glycol), guar gum, polysaccharide, bentonites, sugars, invert sugars, poloxamers (PLURONIC F68, PLURONIC F127), collagen, albumin, celluloses in nonaqueous solvents, and the like or their suitable combinations. Other binders which may be included may be, for example, poly(propylene glycol), polyoxyethylene - polypropylene copolymer, polyethylene ester, polyethylene sorbitan ester, poly(ethylene oxide), microcrystalline cellulose, poly(vinylpyrrolidone), combinations thereof and other such materials known to those of ordinary skill in the art.
As used herein, the term "diluent" or "filler" is intended to mean inert substances used as fillers to create the desired bulk, flow properties, and compression characteristics in the preparation of tablets and capsules. Such compounds include, by way of example and without limitation, dibasic calcium phosphate, kaolin, sucrose, lactose, mannitol, maltodextrin, fructose, maltitol, xylitol, sucrose, microcrystalline cellulose, silicified microcrystalline cellulose, powdered cellulose, precipitated calcium carbonate, sorbitol, starch, pregelantized starch, hydrated sodium sulfoaluminate combinations thereof and other such materials known to those of ordinary skill in the art.
As used herein, the term "glidant" is intended to mean agents used in tablet and capsule formulations to improve flow-properties during tablet compression and to produce an anti caking effect. Such compounds include, by way of example and without limitation, colloidal silica, calcium silicate, magnesium silicate, silicon hydrogel, corn starch, talc, ascorbil
palmitate, calcium palmitate, combinations thereof and other such materials known to those of ordinary skill in the art.
As used herein, the term "lubricant" is intended to mean substances used in tablet formulations to reduce friction during tablet compression. Such compounds include, by way of example and without limitation, calcium stearate, magnesium stearate, sodium stearate, sodium steryl fumarate, talc, sodium lauryl sulfate, mineral oil, stearic acid, zinc stearate, suitable combinations thereof and other such materials known to those of ordinary skill in the art.
As used herein, the term "disintegrant" is intended to mean a compound used in solid dosage forms to promote the disruption of the solid mass into smaller particles which are more readily dispersed or dissolved. Exemplary disintegrants include, by way of example and without limitation, starches such as com starch, potato starch, pre-gelatinized and modified starch (Starch 1500) thereof, sweeteners, clays, such as bentonite, croscarmellose sodium, microcrystalline cellulose (e.g. Avicel™.), crospovidone, polacrilin potassium, methyl cellulose sodium CMC, calcium CMC, HPMC, alginates, alginic acid, low substituted HPC, sodium starch glycolate, gums such as agar, guar, locust bean, karaya, pectin, tragacanth, combinations thereof and other such materials known to those of ordinary skill in the art.
As used herein, the term stabilizers are the compound that maintain the pH of the formulation used according to the present invention include, but are not limited to attapulgite, bentonite, calcium carbonate, calcium phosphate, calcium sulphate, mono ethanolamine, tri ethanolamine, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium benzoate, sodium hydroxide, sodium citrate, sodium sulfite, sodium bicarbonate, sodium carbonate, disodium hydrogen phosphate, mono basic potassium phosphate, dicalcium phosphate, meglumine, light or heavy magnesium oxide and other similar excipients and their suitable combinations and other materials known to those of ordinary skill in the art.
As used herein, the term "carrier polymer" is intended to mean substances used to act as carrier to form complex with API and enhance solubility. Such compounds include, by way of example and without limitation, alkylcellulose such as methylcellulose; hydroxyalkylcellulose such as hydroxyethylcellulose and hydroxypropylcellulose; hydroxyalkylalkylcellulose such as hydroxyethylmethylcellulose and hydroxypropylmethylcellulose; hypromellose acetate succinate, methylcellulose phthalate,
cellulose acetate phthalate, polyethylene glycol, ethylcellulose, pyroxylin, polyethylene oxide, polyvinyl caprolactam-polyvinyl acetate -polyethylene glycol, hydroxypropyl methylcellulose phthalate, hydroxybutylcellulose, carboxymethylcellulose, 60:40 copolymer of N-vinyl-2-pyrrolidone and vinylacetate, sodium carboxymethylcellulose, carboxymethyl- ethylcellulose, cellulose acetate phthalate, methacrylic acid copolymers polyvinyl alcohol; polyvinyl pyrrolidone and combinations thereof. Of these, polyvinyl pyrrolidone is particularly preferable.
The sweetener in the formulations of the present invention selected from a group comprising isomalt, sorbitol, acesulfame, aspartame, alitame, fructose, maltitol, lactitol, xylitol, erythritol, saccharin, sodium cyclamate, sucralose, sucrose, neotame, neohespiridine dihydrochalcone, glycyrrhizin, stevloside, thaumatin, tagatose or suitable combination thereof.
The flavouring agent in the formulations of the present invention selected from a group comprising levomenthol, menthol, anethole, methyl salicylate, eucalyptol, cinnamon, mint, mango, almond, anise, celery, cassia, nutmeg rosemary, savory, basil, sweet marjoram, wintergreen, peppermint, 1-methyl acetate, sage, eugenol, oxanone, lemon, orange, strawberry, blackberry, raspberry, banana, butterscotch, coconut-custard, cinnamon , grinatidine, portwine, gaulterial, peppermint, clove, berry, aniseed, eucalyptus, thyme oil, cedar leaf oil, walnut oil, sage oil, bitter almonds, vanilla, citrus oil, including grape, lime and grapefruit, and fruit essences, including apple, pear, peach, raspberry, cherry, maple, plum, pineapple, apricot or combinations thereof.
As used herein, the term "solvents" is intended to mean a compound or mixture of more than one used to dissolve the API and the carrier polymer in one phase. Examples of the solvent may include, without limitation, water, methanol, ethanol, methylene chloride, acetone, methyl acetate, ethyl acetate, chlorinated solvents, N-methylpyrrolidone (NMP), dimethylsulfoxide (DMSO) or dimethylacetamide (DMAc), n-propanol, isopropanol, butanol, methyl ethyl ketone and methyl isobutyl ketone, ethyl acetate and propylacetate, acetonitrile, toluene, 1,1,1-trichloroethane or suitable combinations thereof.
Suitable coloring agents include, one or more natural and/or artificial colorants such as FD&C coloring agents, natural juice concentrates, pigments such as titanium oxide, silicon dioxide, iron oxides, zinc oxide, and the like.
In one aspect, the present invention provides a stable orodispersible formulation of compounds of formula (I)
Formula (I) or its pharmaceutically acceptable salts.
Preferably, the present invention provides a stable orodispersible tablet formulation of saroglitazar magnesium of compound of formula (I-a).
Formula (I-a) The present invention further describes a stable orodispersible formulation of compounds of formula (I) or its pharmaceutically acceptable salts preferably a compound of formula (I-a), comprising one or more pharmaceutical excipients.
In a preferred embodiment, the orodispersible formulation of compound of formula (I) or its pharmaceutically acceptable salts, preferably a compound of formula (I-a) of the present invention essentially comprises of
(i) a diluent or filler , wherein the diluent or filler is mannitol where 10 % of particles should not be more than 315 μm and 90 % of particles should not be less than 75 μm;
(ii) a disintegrating agent; (iii) a soluble excipients component part more than 50%w/w.
(iv) and one or more pharmaceutically acceptable excipient.
Suitable disintegrating agent in the formulations of the present invention selected from a group comprising croscarmellose sodium, crospovidone, pregelatinized starch, sodium starch glycolate or low-substituted hydroxypropyl cellulose.
Soluble excipients component part is selected from mannitol, lactose, aspartame or mixture thereof.
The other pharmaceutical excipients according to the present invention can be selected from stabilizers, binders, lubricants, glidants, sweeteners, carrier polymer, solvents, flavoring agents and colors and the like as known in the art.
The sweetener in the formulations of the present invention selected from a group comprising isomalt, sorbitol, acesulfame, aspartame, alitame, fructose, maltitol, lactitol, xylitol, erythritol, saccharin, sodium cyclamate, sucralose, sucrose, neotame, neohespiridine dihydrochalcone, glycyrrhizin, stevloside, thaumatin, tagatose or suitable combination thereof.
The flavouring agent in the formulations of the present invention selected from a group comprising levomenthol, menthol, anethole, methyl salicylate, eucalyptol, cinnamon, mint, mango, almond, anise, celery, cassia, nutmeg rosemary, savory, basil, sweet marjoram, wintergreen, peppermint, 1-methyl acetate, sage, eugenol, oxanone, lemon, orange, strawberry, blackberry, raspberry, banana, butterscotch, coconut-custard, cinnamon , grinatidine, portwine, gaulterial, peppermint, clove, berry, aniseed, eucalyptus, thyme oil, cedar leaf oil, walnut oil, sage oil, bitter almonds, vanilla, citrus oil, including grape, lime and grapefruit, and fruit essences, including apple, pear, peach, raspberry, cherry, maple, plum, pineapple, apricot or combinations thereof.
Any conventional gelling matrix forming agent may be used for purposes of the present disclosure. Suitable gelling matrix forming agents include, without limitation, gelling gelatin, carageenan gums, hyaluronic acid, pectins, sodium pectate, starches, carboxymethyl cellulose sodium, agar, gellan gum, xanthan gum, guar gum, tragacanthan gum, hydroxypropyl cellulose, hydroxyethyl cellulose hydroxypropyl methylcellulose, methylcellulose, carbopols, carbomers, poloxamer, polyacrylic acid, polyvinyl alcohol, alginates and poly(glycolic acid) or suitable combinations thereof.
Any of excipients may have more than one role in formulation for example starch used as both binder and glidant in formulation.
In one embodiment of the above aspects, orodispersible formulation according to the present invention comprises from about 0.5 % to about 10 % w/w compound of Formula (I-a).
In one embodiment, the present invention provides a stable orodispersible tablet formulation which disintegrates rapidly by the action of saliva in the oral cavity. In an embodiment, the orodispersible tablet of the present invention disintegrates in less than 60 seconds, preferably in less than 40 seconds.
In one embodiment, the orodispersible tablet formulation of the present invention comprises compound of formula (I) or its pharmaceutically acceptable salts, preferably compound of formula (I-a) having particle size (D90) of is less than 200 μm, preferably less than 100 μm, more preferably less than 75μm.
The orodidpersable formulation of the present invention comprise orodispersable tablet formulation of compound of formula (I) or its pharmaceutically acceptable salts, preferably compound of formula (I-a) with good disintegration characteristics and pharmacokinetics, which provide improved compliance for patients in need thereof.
In one embodiment, the orodispersible tablet formulation of the present invention may further comprise one or more known impurities and if present their individual limit should not be more than 1.5 %.
In a further embodiment, the orodispersible tablet formulation of the present invention may further comprise one or more unknown impurities and if present their individual limit should not be more than 0.5%.
In a further another embodiment, the orodispersible tablet formulation comprising a therapeutically effective amount of compound of formula (I) or its pharmaceutically acceptable salt preferably compound of formula (I-a) and a pharmaceutically acceptable excipient, wherein the composition provides a serum or plasma profile comprising a mean of Cmax of from about 19.50 ng/ml to about 850 ng/ml, when administered to the patient in need thereof.
In one embodiment, the pharmaceutical composition comprising a therapeutically effective amount of compound of formula (I) or its pharmaceutically acceptable salt preferably compound of formula (I-a) and a pharmaceutically acceptable excipient, wherein the composition provides a serum or plasma profile comprising a mean of AUClast of from about 46.50 hr*ng/ml to about 2050 hr*ng/ml, when administered to the patient in need thereof.
In one embodiment, the pharmaceutical composition comprising a therapeutically effective amount of compound of formula (I) or its pharmaceutically acceptable salt preferably compound of formula (I-a) and a pharmaceutically acceptable excipient, wherein the composition provides a serum or plasma profile comprising a Tmax of from about 0.25 hr to about 2.0 hr, when administered to the patient in need thereof.
In one embodiment, the orodispersible tablet formulation of the present invention may be packed in suitable size HDPE bottle pack or Blister pack or Blister in pouch pack using appropriate desiccant and/or oxygen scavenger and/or packaging component under nitrogen environment. This may help to stabilize the drug product to control the moisture and oxygen sensitive impurities.
Orodispersible formulation according to the present invention may be in the form of a tablet or capsule or a powder or a suspension in a liquid or an aerosol formulation or solutions, preferably in the form of a tablet.
In one of the embodiment, the orodispersible formulations prepared according to the present invention comprise Saroglitazar magnesium in the range of about 0.5% to about 8 % (w/w), disintegrant in the range of about 1% to about 10 % (w/w), binder in the range of about 0.1 % to about 15 %, diluent in the range of about 5 % to about 90% (w/w), wetting agent in the range of about 2 % to about 20%, alkanilizer agent in the range of about 1% to about 16% (w/w), glidant in the range of about 0.1% to about 2.0 % (w/w), sweetener in the range of about 0.1% to about 50% (w/w), antioxidant in the range of about 0.1 % to about 10 %, gelling matrix forming agent in the range of about 0.1% to about 20%, carrier polymer in the range of about 0.5% to about 50%, solvents in the range of about 2% to about 90%, flavoring agent in the range of about 0.1% to about 8 % (w/w) and lubricant in the range of about 0.1% to about 4% (w/w) in proportion to total weight of unit dose.
In a preferred embodiment, the orodispersible formulation prepared according to the present invention as disclosed in example 1-7.
The orodispersible formulation may be made by direct compression, wet granulation, dry granulation, lyophilization, solid dispersion or top spray granulation methods by techniques known to persons skilled in the art. Thus, for example,
In wet granulation process, the drug is mixed with one or more pharmaceutical excipients and granulated with suitable binding solution as described earlier, to form wet granules; the wet granules are dried and optionally sieved. The dried granules are mixed with one or more suitable excipients from those described elsewhere and then compressed into tablets or filled into capsules.
In direct compression process, the drug is mixed with all the pharmaceutical excipients required and then is compressed into tablets.
In dry granulation process the drug is mixed with one or more pharmaceutical excipients and compressed into slugs and these slugs are passed through required size of sieve. The sieved granules are mixed with one or more suitable excipients from those described elsewhere and then compressed into tablets or filled into capsules.
In lyophilization process the drug is suspended in water with one or more suitable pharmaceutical excipients with or without help of homogenization. The resultant suspension is accurate filled in suitable aluminum blister and lyophilized. The lyophilized tablets are sealed in the blister pack.
In solid dispersion process the drug and a suitable polymer are dissolved in a common solvent or mixture of solvents to form drug polymer complex. The remaining excipients are passed through required size of sieve and granulated with the drug polymer solution under controlled process. The wet granules are dried and optionally sieved. The dried granules are mixed with one or more suitable excipients from those described elsewhere and then compressed into tablets.
In top spray granulation process the drug is dissolved in a suitable solvent or mixture of solvents. The bulk of one or more excipients are passed through appropriate size of sieve and granulated with the drug solution under controlled process. The wet granules are dried and optionally sieved. The dried granules are mixed with one or more suitable excipients from those described elsewhere and then compressed into tablets.
In another aspect of the present invention, provides processes for the preparation of a stable pharmaceutical composition of compounds of formula (I), preferably a compound of formula (I-a).
Manufacturing process comprises following techniques: 1. Wet Granulation
2. Direct compression
3. Dry-granulation
4. Lyophilization
5. Solid dispersion 6. Top spray granulation
The invention is further exemplified by the following non-limiting example, which is illustrative representing the preferred modes of carrying out the invention. The invention’s scope is not limited to these specific embodiments only but should be read in conjunction with what is disclosed anywhere else in the specification together with those information and knowledge that are within the general understanding of a person skilled in the art.
Brief manufacturing Process of ODT (Direct Compression)
1. All excipients and compound of formula (I-a) are weighed accurately.
2. Compound of formula (I-a) is mixed with part quantity of mannitol and sifted through sieve #30.
3. Magnesium oxide light is mixed with remaining quantity of mannitol and sifted through sieve #30.
4. Half material of step 3 and complete material of step 2 and then remaining half material of step 3 are added in conta blender and blended for 5 min at 18 RPM.
5. Iron oxide red is sifted with of microcrystalline cellulose through sieve #40 and kept aside.
6. Remaining microcrystalline cellulose, crospovidone, colloidal silicon dioxide, peppermint and aspartame are sifted through sieve #40 with material of step 5 and added them to blender and blended for 15 min at 18 RPM.
7. Magnesium stearate is sifted through #60 and added into step 6 and blend is lubricated for 5 min at 18 RPM.
8. Final lubricated blend is compressed in to tablets.
Brief manufacturing Process of ODT (Lyophilization)
1. Mannitol and gelatin are dissolved in purified water heated at 60°C under stirring.
2. Once clear solution obtained, magnesium oxide and compound of formula (I-a) are suspended in to it under stirring.
3. The suspension of step 2 is homogenized using high speed homogenizer.
4. The resultant suspension is accurately filled by specified weight in to pockets of aluminum blister and lyophilized.
5. The prepared tablets are packed in the blisters pack.
*Does not remain in the final product
Brief manufacturing Process of ODT (Solid dispersion)
1. Compound of formula (I-a) and polyvinylpyrrolidone are dissolved in dichloromethane system under stirring.
2. Intragranular excipients (magnesium oxide light, mannitol, crospovidone and microcrystalline cellulose) are weighed accurately and mixed properly in suitable granulator.
3. To the dry blend of step 2, API polymer solution is added and the blend is granulated.
4. The wet mass of step 3 is passed through # 10 and the wet granules are dried in fluid bed dryer at temperature below 35°C.
5. The dried granules of step 4 are milled to get uniform granules.
6. Colloidal silicon dioxide, peppermint flavor and aspartame are weighed and passed along with the milled granules of step 5 through # 30.
7. The above blend is mixed in the conta blender
8. Talc and magnesium stearate are added and mixed.
9. The final blend is compressed to make the tablet dosage form.
*Does not remain in the final product
Brief manufacturing process (Top spray granulation)
1. Compound of formula (I-a) are dissolved in suitable solvent or solvent system under stirring.
2. Intragranular excipients (magnesium oxide light, mannitol, crospovidone and microcrystalline cellulose) are weighed accurately and mixed and loaded in to fluidized bed granulator.
3. The dry blend is granulated using the API solution using top spray granulation technique.
4. The wet granules of step 3 are dried in fluid bed dryer at temperature below 35°C.
5. The dried granules of step 4 are milled to get uniform granules.
6. Colloidal silicon dioxide, peppermint flavor and aspartame are weighed and passed along with the milled granules of step 5 through # 30.
7. The above blend is mixed in the conta blender.
8. Talc and magnesium stearate are added and mixed.
9. The final blend is compressed to make the tablet dosage form.
1.0. Wet Granulation
Suitable intragranular excipients and compound of formula (I- a) are weighed accurately and mixed properly in suitable granulator. To the dry blend, IPA is added and the blend is granulated. The wet mass is passed through # 10 and the wet granules are dried in fluid bed dryer at temperature below 60°C. The dried granules are milled to get uniform granules. Colloidal silicon dioxide, peppermint flavor and aspartame are weighed and passed along
with the dried granules through # 30. The above blend is mixed with the granules in the conta blender and to the dried mass; talc and magnesium stearate are added and mixed. The final blend is compressed to make the tablet dosage form. 2.0 Dry granulation
Suitable excipients and compound of formula (I-a) are mixed and passed through a roller compactor. Obtained compressed powder/slug is then subjected to milling to get uniform particle size granules which are further lubricated and compressed to make tablet dosage form. Table 1 given below shows stability data of stable orodispersible tablet formulation of Example- 1 as exemplified above.
Tables 2, 3 and 4 given below show analytical data of orodispersible tablet formulation of Example-6, Example-7 and Example-8 respectively as exemplified above.
Table 5 given below shows stability data of stable orodispersible tablet formulation of Example-4 as exemplified above.
Saroglitazar magnesium ODT dosage form have better advantage over conventional immediate release (IR) dosage form, where disintegration time is observed less than 60 seconds. Saroglitazar magnesium ODT having higher soluble fraction of excipients (more than 70%) as well as sweetner and flavoring agents which make ODT formulation more patient compliant. The higher soluble fraction of excipient along with sweetner and flavoring agent renders pleasant mouth feeling.
IR formulation of Saroglitazar as mentioned here can be prepared according to the US patent No. US 10098868 B2.
Table 6 given below shows comparative data of stable orodispersible tablet formulation and IR formulation of Compound of formula (I) or its pharmaceutically salts, preferably Compound of formula (I- a).
Table 7 given below shows comparative In-vitro dissolution data of stable ODT formulation and IR formulation. Despite of change in the formulation composition of Saroglitazar magnesium ODT formulation, the dissolution profile of Saroglitazar magnesium ODT formulation found comparable to conventional IR formulation.
Orodispersible Tablets (OPT)
Objective:
To assess the bioequivalence of Saroglitazar magnesium OD Tablets 2 mg in healthy, adult, human subjects under fasting conditions.
Test Product: Saroglitazar magnesium OD tablet 2 mg
Reference Product: Saroglitazar magnesium IR tablet 2 mg
Design of Study:
An Open-label, balanced, randomized, two-treatment, two-sequence, two-period, crossover, single dose, oral bioequivalence study in 13 healthy, adult, human subjects under fasting conditions were carried out to assess the bioequivalence of Saroglitazar magnesium OD Tablets 2 mg in healthy, adult, human subjects under fasting conditions against Saroglitazar magnesium Immediate release Tablets 2 mg.
Procedure of Test and Reference Product administration:
Test Product: After an overnight fasting of at least 10 hours, subjects were administered a single 2 mg oral dose of Test Product in a sitting posture without drinking water as per randomization schedule. Subjects were required to place the Test Product on the tongue without crushing or breaking the tablet with teeth till it completely dispersed in saliva and then subjects were allowed to swallow the content without administration of water. Subjects were allowed to wet the mouth by swallowing 20 ml of 20% Glucose solution 10 min before placing the ODT on the tongue.
Reference Product: After an overnight fasting of at least 10 hours, subjects were administered a single 2 mg oral dose of Reference Product in a sitting posture with about 240 ± 2 mL of 20% Glucose solution at ambient temperature as per randomization schedule.
Summary Results:
The summary of Pharmacokinetic results is detailed below.
Table 1: Summary of Pharmacokinetic results (N=13)
^Median Tmax
Based on the pharmacokinetic results, it is observed that Cmax, AUC0-t and AUC0-I value of Saroglitazar magnesium OD Tablets 2 mg are comparable to Saroglitazar magnesium immediate release tablets 2 mg.
References:
1. Shyamala B, Narmada GY. Rapid dissolving tablets: A novel dosage form. The Indian Pharmacist, 2002; 13(8): 09-12.
2. Valleri M, Mura P, Maestrelli F, Cirri M, Ballerini R. Development and evaluation of glyburide fast dissolving tablets using solid Dispersion technique. Drug Dev Ind Pharm,
2004; 30(5): 525-34.
3. Hanawa T, Watanabe A, Tsuchiya T, Ikoma R, Hidaka M, Sugihara M. New Oral dosage form for elderly patients: Preparation and characterization of silk fibroin gel. Chem Pharm Bull, 1995; 43(2): 284-288. 4. Mallet L. Caring for the Elderly Patient. J. Am. Pharm.Assoc, 1996; 36(11): 628-635.
5. Porter SC. Novel drug delivery: Review of recent trends with oral solid dosage forms. Am Pharm Rev, 2001; 85: 28-35.
6. Sreenivas SA, Dandagi PM, Gadad AP, Godbloe AM, Hiremath SP, Mastiholimath VS. Orodispersible tablets: New-fangled drug delivery systems - A review. Indian J Pharm Educ Res, 2005; 39(4): 177-181. . Seager H. Drug-delivery products and Zydis Fastdissolving dosage form. J Pharm Pharmacol, 1998; 50: 375-382.
8. Bradoo R, Shahani S, Deewan B, Sudarshan S. Fast dissolving drug delivery system. J Am Med Assoc India, 2001; 4 (10): 27-31.
9. Lies MC, Atherton AD, Copping NM. Freeze-dried dosage forms and methods for preparing same. US Patent 5,188,825 (1993). 10. Sugihara M, Hidaka M, Saitou A. Discriminatory features of dosage form and package. Jpn J Hosp Pharm, 1986; 12: 322-328.
11. Pfister WR, Ghosh TK. Intraoral delivery systems: An overview, current status and future trends. In: Pfister WR, Ghosh TK (Eds). Drug delivery to the oral cavity: Molecules to Market. CRC Press, NY, USA, 2005, 1-40.
Claims
Formula (I) or its pharmaceutically acceptable salt comprising,
(i) a diluent or filler , wherein the diluent or filler is mannitol where 10 % of particles should not be more than 315 μm and 90 % of particles should not be less than 75 μm;
(ii) a disintegrating agent;
(iii) a soluble excipients component part more than 50%w/w.
(iv) and one or more pharmaceutically acceptable excipient.
2. The orodispersible formulation as claimed in claim 1, wherein the pharmaceutically acceptable salt is Mg salt.
3. The orodispersible formulation as claimed in claim 2, having particle size distribution having D90 value of less than 200 μm, preferably less than 100 μm, more preferably less than 75μm.
4. The orodispersible formulation as claimed in any preceding claim of claims 1 to 3 is in the form of a tablet or a caplet or a capsule or a powder or a suspension in a liquid or an aerosol formulation or solutions, preferably in the form of a tablet.
5. The orodispersible formulation as claimed in claim 4, wherein the orodispersible tablet is able to disintegrate in the buccal cavity upon contact with saliva by formation of an easy-to-swallow suspension, in less than 60 seconds, more preferably less than
40 seconds.
6. The orodispersible formulation as claimed in claim 1, wherein the soluble excipients component part is selected from mannitol, lactose, aspartame or mixture thereof.
7. The orodispersible formulation as claimed in claim 1, wherein the pharmaceutical excipient is selected from stabilizers, diluent or filler, lubricants, glidants, sweeteners, flavoring agents and colors or suitable combination thereof.
8. The orodispersible formulation as claimed in claim 1, wherein the disintegrating agent is selected from croscarmellose sodium, crospovidone, pregelatinized starch, sodium starch glycolate or low-substituted hydroxypropyl cellulose.
9. The orodispersible formulation as claimed in claim 1 or 7, wherein the disintegrating agent is present in 1 to 10% by weight, based on the weight of the tablet.
10. The orodispersible formulation as claimed in claim 1, wherein the diluent or filler is present in 5 to 90% by weight, based on the weight of the tablet.
11. The orodispersible formulation as claimed in claim 6, wherein the sweetener is present in 0.1 to 50% by weight, based on the weight of the tablet.
12. The orodispersible formulation as claimed in claim 6, wherein the flavoring agent is present in 0.1 to 8% by weight, based on the weight of the tablet.
13. The orodispersible formulation as claimed in claim 6, wherein the glidant is present in 0.1 to 2% by weight, based on the weight of the tablet.
14. The orodispersible formulation as claimed in claim 6, wherein the lubricant is present in 0.1 to 4% by weight, based on the weight of the tablet.
15. The orodispersible formulation as claimed in claim 6, wherein the flavoring agents is selected from levomenthol, menthol, anethole, methyl salicylate, eucalyptol, cinnamon, mint, mango, almond, anise, celery, cassia, nutmeg rosemary, savory, basil, sweet marjoram, wintergreen, peppermint, 1-methyl acetate, sage, eugenol, oxanone, lemon, orange, strawberry, blackberry, raspberry, banana, butterscotch, coconut-custard, cinnamon, grinatidine, portwine, gaulterial, peppermint, clove, berry, aniseed, eucalyptus, thyme oil, cedar leaf oil, walnut oil, sage oil, bitter almonds, vanilla, citrus oil, including grape, lime and grapefruit, and fruit essences, including apple, pear, peach, raspberry, cherry, maple, plum, pineapple, apricot or combinations thereof.
16. An orodispersible formulation comprising a therapeutically effective amount of Saroglitazar or its pharmaceutically acceptable salt preferably Saroglitazar magnesium and a pharmaceutically acceptable excipient, wherein the formulation provides a serum or plasma profile comprising a mean of Cmax of from about 19.50 ng/ml to about 850
ng/ml, when administered to the patient in need thereof.
17. An orodispersible formulation comprising a therapeutically effective amount of Saroglitazar or its pharmaceutically acceptable salt preferably Saroglitazar magnesium and a pharmaceutically acceptable excipient, wherein the formulation provides a serum or plasma profile comprising a mean of AUQast of from about 46.50 hr.ng/ml to about 2050 hr.ng/ml, when administered to the patient in need thereof.
18. An orodispersible formulation comprising a therapeutically effective amount of or its pharmaceutically acceptable salt preferably Saroglitazar magnesium and a pharmaceutically acceptable excipient, wherein the formulation provides a serum or plasma profile comprising a Tmax (median) of from about 0.25 hr to about 2.0 hr, when administered to the patient in need thereof.
19. A pharmaceutical composition comprising:
(i) from 0.5 to 10 % by weight of Saroglitazar or its pharmaceutically acceptable salt; more prefarably between 0.5 to 5%.
(ii) from 1 to 10 % by weight of a disintegrant selected from croscarmellose sodium, crospovidone, pregelatinized starch, sodium starch glycolate or low-substituted hydroxypropyl cellulose; more preferably crospovidone.
(v) Having soluble fraction of excipients more than 50%w/w
(iii) from 5 to 90 % by weight of a diluent selected from microcrystalline cellulose, lactose, starch or mannitol; more preferably mannitol and microcrystalline cellulose
(iv) from 1 to 16 % by weight of an stabilizing agent selected from meglumine, light or heavy magnesium oxide; more preferably magnesium oxide light
(v) from 0.1 to 50 % by weight of a sweetner selected from aspartame, sucralose, neotame, sacharrine; more preferably aspartame
(vi) from 0.1 to 8 % by weight of a flavouring agent selected from peppermint flavour, vanilla flavour; more preferably peppermint
(vii) from 0.1 to 15 % by weight of a glidant selected from colloidal silicon dioxide, calcium silicate and magnesium silicate; more preferably colloidal silicon dioxide
(vii) from 0.1 to 4 % by weight of a lubricant from calcium stearate, magnesium stearate, sodium stearate, stearic acid and sodium steryl fumarate; more preferably magnesium stearate
20. A method of treatment for primary biliary cholangitis (PBC) in a patient comprising administering to a patient in need thereof the pharmaceutical composition as claimed in claim 1.
21. A method of treatment for primary biliary cholangitis (PBC) in a patient comprising administering to a patient in need thereof the pharmaceutical composition as claimed in claim 19.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202121008278 | 2021-02-26 | ||
IN202121008278 | 2021-02-26 | ||
IN202121036884 | 2021-08-14 | ||
IN202121036884 | 2021-08-14 | ||
IN202121044137 | 2021-09-29 | ||
IN202121044137 | 2021-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022180612A1 true WO2022180612A1 (en) | 2022-09-01 |
Family
ID=83048950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/051711 WO2022180612A1 (en) | 2021-02-26 | 2022-02-26 | Orodispersible formulation of hypolipidemic agent |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022180612A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018104916A1 (en) * | 2016-12-09 | 2018-06-14 | Cadila Healthcare Limited | Treatment for primary biliary cholangitis |
WO2020165782A1 (en) * | 2019-02-13 | 2020-08-20 | Cadila Healthcare Limited | Treatment for polycystic ovarian syndrome (pcos) |
-
2022
- 2022-02-26 WO PCT/IB2022/051711 patent/WO2022180612A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018104916A1 (en) * | 2016-12-09 | 2018-06-14 | Cadila Healthcare Limited | Treatment for primary biliary cholangitis |
WO2020165782A1 (en) * | 2019-02-13 | 2020-08-20 | Cadila Healthcare Limited | Treatment for polycystic ovarian syndrome (pcos) |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6092936B2 (en) | Method for producing orally disintegrating tablets | |
AU728526B2 (en) | Pharmaceutical formulations comprising amoxocyllin and clavulanate | |
US20100016322A1 (en) | Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same | |
US10441585B2 (en) | Formulations containing nalbuphine and uses thereof | |
JP5600747B2 (en) | Oral dispersible formulation | |
AU2007338359B2 (en) | Pharmaceutical formulation comprising neurokinin antagonist | |
US20090263478A1 (en) | Carvedilol forms, compositions, and methods of preparation thereof | |
US20110189274A1 (en) | Stable Pharmaceutical Compositions Of Montelukast Or Its Salts Or Solvates Or Hydrates | |
US20030124187A1 (en) | Pharmaceutical formulations comprising amoxycillin and clavulanate | |
WO2018078644A1 (en) | Orally disintegrating tablets of eltrombopag | |
US11872317B2 (en) | Pharmaceutical composition containing acetominophen and ibuprofen | |
US20090124657A1 (en) | Pharmaceutical compositions comprising montelukast | |
Agiba et al. | Insights into formulation technologies and novel strategies for the design of orally disintegrating dosage forms: A comprehensive industrial review | |
JP2022534159A (en) | Micronized solid melatonin composition | |
US20090269393A1 (en) | Chewable Bilayer Tablet Formulation | |
JP6061924B2 (en) | Oral dispersible formulation | |
WO2022180612A1 (en) | Orodispersible formulation of hypolipidemic agent | |
JP2019019125A (en) | Orally disintegrating tablet and method for producing the same | |
ES2742400T3 (en) | Pharmaceutical formulation of N- [5- [2- (3,5-dimethoxyphenyl) ethyl] -2H-pyrazol-3-yl] -4 - [(3R, 5S) -3,5-dimethylpiperazin-1-yl] benzamide | |
Saju | Formulation Development and Evaluation of Mouth Dissolving Tablets of Diltiazem Hydrochloride by Direct Compression Method | |
TR2022013352A2 (en) | ORAL PHARMACEUTICAL FORMULATIONS | |
JP2023502209A (en) | Orally disintegrating pharmaceutical composition of apixaban |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22759072 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22759072 Country of ref document: EP Kind code of ref document: A1 |